Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multinational, Multicenter Study With an Open-Label Phase 1b and a Randomized, Double-Blind, Placebo-Controlled Phase 3 Followed by an Open-Label Extension to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of Radiprodil in Participants With GRIN-Related Neurodevelopmental Disorder

NCT07224581 is registered in ClinicalTrials.gov with GRIN Therapeutics, Inc. as lead sponsor.

NCT NCT07224581
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07224581 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multinational, Multicenter Study With an Open-Label Phase 1b and a Randomized, Double-Blind, Placebo-Controlled Phase 3 Followed by an Open-Label Extension to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of Radiprodil in Participants With GRIN-Related Neurodevelopmental Disorder
Lead sponsor
GRIN Therapeutics, Inc.
Phase
Phase 3
Overall status
Recruiting
Start date
January 5, 2026
Completion date
July 31, 2028
Enrollment
100 (estimated)
Sites
34

Conditions

As the registry lists them; a condition with its own page is linked.

grin-related neurodevelopmental disorder